share_log

三葉草生物-B:截至2024年3月31日止月份股份發行人的證券變動月報表

CLOVER BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended March 31, 2024

HKEX ·  Apr 3 17:14

Summary by Futu AI

三葉草生物製藥有限公司(「三葉草生物-B」)於2024年4月3日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年3月31日的股份變動情況。報告顯示,公司的法定/註冊股本維持不變,總額為200,000美元,每股面值0.0001美元,總股份數目為2,000,000,000股。在股份期權方面,根據2021年4月15日通過的首次公開發售前購股權計劃,本月內有52,500股份期權被行使,同時有26,000股份期權失效。此外,根據2021年9月26日通過的首次公開發售後購股權計劃,本月內有1,315,986股份期權失效。本月內因行使期權所得資金總額為420港幣。公司確認所有證券發行均已獲董事會批准,並符合香港聯合交易所有限公司證券上市規則的要求。
三葉草生物製藥有限公司(「三葉草生物-B」)於2024年4月3日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年3月31日的股份變動情況。報告顯示,公司的法定/註冊股本維持不變,總額為200,000美元,每股面值0.0001美元,總股份數目為2,000,000,000股。在股份期權方面,根據2021年4月15日通過的首次公開發售前購股權計劃,本月內有52,500股份期權被行使,同時有26,000股份期權失效。此外,根據2021年9月26日通過的首次公開發售後購股權計劃,本月內有1,315,986股份期權失效。本月內因行使期權所得資金總額為420港幣。公司確認所有證券發行均已獲董事會批准,並符合香港聯合交易所有限公司證券上市規則的要求。
Clover Biopharmaceuticals Limited (“Clover Bio-B”) filed with Hong Kong Trading and Settlement Limited on 3 April 2024 with Hong Kong Trading and Settlement Limited, reporting the stock changes as of 31 March 2024. The report showed that the company's regulated/registered share capital remained unchanged, totaling $200,000, with a face value of $0.0001 per share, and the total number of shares was 2,000,000,000 shares. In terms of stock options, 52,500 share options were exercised during the month and 26,000 share options expired under the Initial Public Offering Plan approved on April 15, 2021. In addition, 1,315,986 share options expired this month under the Initial Public Offering Possession Option Plan approved on September 26, 2021. The total amount of capital gained from the exercise of options during the month was HK$420. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Clover Biopharmaceuticals Limited (“Clover Bio-B”) filed with Hong Kong Trading and Settlement Limited on 3 April 2024 with Hong Kong Trading and Settlement Limited, reporting the stock changes as of 31 March 2024. The report showed that the company's regulated/registered share capital remained unchanged, totaling $200,000, with a face value of $0.0001 per share, and the total number of shares was 2,000,000,000 shares. In terms of stock options, 52,500 share options were exercised during the month and 26,000 share options expired under the Initial Public Offering Plan approved on April 15, 2021. In addition, 1,315,986 share options expired this month under the Initial Public Offering Possession Option Plan approved on September 26, 2021. The total amount of capital gained from the exercise of options during the month was HK$420. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.